Biosynth Secures $100

Biosynth, a global provider of critical raw materials and services for the diagnostics, vaccines, and pharmaceutical sectors, has secured $100,000 in new funding.

This investment will support the company's ongoing efforts to supply essential components and services to the life sciences industry.

Biosynth's mission centers on de-risking supply chains for its customers by providing high-quality chemical and biological products.

The company operates at the intersection of chemistry and biology, offering expertise in complex chemicals, peptides, and key biologics.

Biosynth serves as a trusted partner for pharmaceutical, life science, and diagnostic sectors, as well as customers in food, agrochemistry, and cosmetics.

With facilities across three continents and a rapid global distribution network, Biosynth manufactures and sources a vast range of chemical and biochemical products, specializing in complex chemistry and delivering products that meet stringent quality standards.

Its services include enzyme development, biocatalysis, and reagents for in vitro diagnostics.

This capital infusion of $100,000 is intended to further Biosynth's strategic objectives and enhance its operational capabilities.

The company plans to use the funds to support targeted growth initiatives, ensuring it can continue to expand its product offerings and service portfolio.

This investment underscores Biosynth's commitment to innovation and its role in supporting global life science research and development.

Looking ahead, Biosynth aims to strengthen its position as a leading supplier and manufacturer, continuing to secure supply chains with consistent quality across the globe.

The company remains focused on expanding its capabilities in custom synthesis and manufacturing services, supporting scientists with critical raw materials from milligram to ton scale production.